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1. Introduction 
The bone marrow of adult humans is a source of endothelial progenitor cells (EPCs) that 
circulate in the blood and repair damaged endothelium. The number and function of EPCs 
is predictive of endothelial function and cardiovascular events. Herein we discuss the 
impact of individual risk factors on EPC numbers and discuss the potential utility of EPC 
number as a cardiovascular risk-assessment tool that integrates traditional and emerging 
cardiovascular risk factors.   
2. The systemic basis of cardiovascular disease 
Cardiovascular disease the leading cause of mortality in the Western world and manifests as 
coronary disease, peripheral vascular disease, or ischemic stroke depending on the vascular 
territory affected. The ageing population and projected increases in prevalence and costs of 
care have highlighted the need for more effective prevention of cardiovascular disease 
(Heidenreich, Trogdon et al. 2011). These manifestations of cardiovascular disease share 
common risk factors of age, hypertension, diabetes, hypercholesterolemia and smoking 
(Roger, Go et al. 2011). Endothelial dysfunction is the precursor lesion to atherosclerosis and 
reflects depressed nitric oxide (NO) release from the endothelium (Furchgott 1996; 
Valgimigli, Merli et al. 2003). Basal release of NO from the endothelium regulates vascular 
tone and antagonizes the actions of vasoconstrictor substances. Further, NO possesses anti-
platelet actions and down-regulates adhesion molecules that attract inflammatory cells to 
the endothelium (Deanfield, Halcox et al. 2007). The degree of endothelial dysfunction 
shows a graded response to the number of cardiac risk factors present (Bonetti, Lerman et al. 
2003; Davignon and Ganz 2004) and is predictive of clinical events (Bonetti, Lerman et al. 
2003; Davignon and Ganz 2004; Deanfield, Halcox et al. 2007). Since endothelial dysfunction 
occurs systemically, the atherosclerotic process involves a large portion of the arterial tree 
before it becomes clinically manifest (Deanfield, Halcox et al. 2007). Patient presentations to 
a cardiologist, cardiac surgeon, vascular surgeon or stroke neurologist with clinically 
manifest atherosclerosis are typically preceded by decades of endothelial dysfunction and 
depressed vascular repair throughout the entire arterial bed (Ross 1993). The systemic 
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nature of atherosclerosis is highlighted by the fact that >50% of patients with stroke or 
peripheral vascular disease have co-morbid atherosclerotic coronary disease (Hirsch, Haskal 
et al. 2006; Brott, Halperin et al. 2011) and patients with manifest disease in multiple arterial 
beds are at an increased risk of cardiovascular death and recurrent events (Steg, Bhatt et al. 
2007). Since the description of circulating marrow cells that repair the endogenous arterial 
bed, “endothelial progenitor cells” (EPCs), an increasing research interest has been focused 
on how risk factors impact on the numbers of these cells and their ability to repair the 
vasculature and maintain endothelial function. 
3. Endothelial progenitor cells and atherosclerosis 
The modern concept that circulating marrow cells, EPCs, circulate in adult animals and 
repair the vasculature originates stems from the observation in the late 90s that marrow-
derived mononuclear cells circulate in adult animals and directly contribute to 
neovascularization in animal models of hindlimb ischemia, myocardial infarct remodeling 
and post-stroke neovascularization (Asahara, Murohara et al. 1997; Asahara, Masuda et al. 
1999; Zhang, Zhang et al. 2002; Metharom and Caplice 2007). The clinical relevance of EPC 
numbers was brought to the forefront cardiovascular risk prognostication when EPC 
numbers were shown to correlate positively with flow mediated brachial artery reactivity (a 
measure of endothelial function) and inversely with the Framingham risk score (Hill, Zalos 
et al. 2003; Ghani, Shuaib et al. 2005; Chironi, Walch et al. 2007). Endothelial dysfunction 
observed in patients with cardiovascular disease or its risk factors may reflect a depressed 
ability to “renew” the endothelium from the circulating pool of EPCs which act to restore 
endothelial function. Indeed, patients with coronary artery disease (CAD) and stroke were 
shown to have EPC numbers that are reduced when compared to age-matched healthy 
volunteers (Vasa, Fichtlscherer et al. 2001; Lambiase, Edwards et al. 2004; Ghani, Shuaib et 
al. 2005). EPC numbers, which are usually assessed by flow cytometry for CD34+KDR+ 
cells, carry prognostic significance in patients with and without cardiovascular disease. EPC 
numbers predict clinical events in patients with established CAD. Amongst patients with 
CAD, lower EPC numbers were associated with increased severity of CAD and higher risks 
of death from cardiovascular causes, major cardiovascular events, revascularization or 
hospitalization (Schmidt-Lucke, Rossig et al. 2005; Werner, Kosiol et al. 2005; Kunz, Liang et 
al. 2006; Wang, Gao et al. 2007). In asymptomatic individuals, EPC numbers correlate with 
the number of vascular beds with subclinical disease. In a study using ultrasound to 
characterize disease in the carotid artery, abdominal aorta and femoral artery, the number of 
EPCs cells was shown to be decreased stepwise in patients with plaque in 0, 1, 2 and 3 of the 
sites (Chironi, Walch et al. 2007). Further, EPC numbers correlate with cardiovascular 
disease surrogates such as carotid intima-media thickness even after correction for the 
Framingham risk score and C-reactive protein (Fadini, Coracina et al. 2006). 
In addition to absolute EPC numbers, the functional capacity of EPCs in repairing the 
vasculature is impaired by cardiac risk factors. EPCs harvested from the marrow of human 
patients with ischemic cardiomyopathy show an impaired capacity to effect 
neovascularization and incorporate into the vasculature in a mouse hindlimb ischemia 
model (Heeschen, Lehmann et al. 2004). In a human trial testing the efficacy of EPCs in 
repairing the coronary vasculature after a re-perfused myocardial infarction, the migratory 
capacity of EPCs to chemotaxins was the strongest multivariate predictor of reduction in 
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infarct size (Britten, Abolmaali et al. 2003). Reduced EPC migration to chemotaxins and 
reduced ability of human EPCs to effect neovascularization in animal hindlimbs has also 
been related to individual cardiovascular risk factors such as increasing age, hypertension, 
hypercholesterolemia, family history of CAD, smoking and high Framingham risk scores 
(Vasa, Fichtlscherer et al. 2001; Hill, Zalos et al. 2003; Heeschen, Lehmann et al. 2004; 
Schmidt-Lucke, Rossig et al. 2005; Wang, Gao et al. 2007). While EPCs can be harvested from 
bone marrow to treat myocardial ischemia (Britten, Abolmaali et al. 2003) or threatened limb 
ischemia (Comerota, Link et al. 2010) on an investigational basis, herein we focus on the 
impact of cardiovascular risk factors on EPCs and the potential utility of measuring EPC 
numbers for risk assessment in primary and secondary prevention. We discuss the impact of 
individual risk factors on EPC number with a focus on studies undertaken in human 
subjects and describe how risk factor control boosts EPC numbers. Each of the discussed risk 
factors individually suppresses EPC mobilization from the marrow and decreases 
peripheral survival making EPC number a universal risk factor (Hoenig, Bianchi et al. 2008).  
4. Insulin resistance, the metabolic syndrome and diabetes 
Diabetes is a risk factor associated with heightened cardiovascular risk and endothelial 
dysfunction (De Vriese, Verbeuren et al. 2000; III 2002). In some series, diabetes has been 
associated with the same coronary risk as established coronary disease thereby making it a 
“coronary artery disease risk-equivalent” (Haffner, Lehto et al. 1998). Diabetics without 
manifest cardiovascular disease have decreased EPC numbers compared to age-matched 
controls (Tepper, Galiano et al. 2002) and diabetics with manifest macrovascular disease 
such as CAD, peripheral vascular disease or stroke have further reduced EPC numbers 
(Fadini, Miorin et al. 2005; Brunner, Hoellerl et al. 2011). Further, EPCs in diabetics are 
dysfunctional when compared to EPCs from non-diabetic subjects. The depressed EPC 
numbers in diabetes are thought to contribute to impaired collateralization of vascular 
ischemic beds (Waltenberger 2001) and may predispose this group to developing non-
healing diabetic ulcers which may be ameliorated by injecting EPCs into ischemic lower 
limb muscles (Huang, Li et al. 2005). Indeed, among diabetic patients with peripheral 
vascular disease, EPC numbers correlated negatively with the ankle brachial index and 
patients with ischemic ulcers had the lowest EPC numbers (Fadini, Miorin et al. 2005). Blood 
sugar levels are inversely correlated with EPC numbers implying a direct relationship 
between hyperglycemia and depressed EPC numbers (Fadini, Miorin et al. 2005). In the 
laboratory, hyperglycemia directly impairs EPC function by impairing the ability of these 
cells to migrate (Krankel, Adams et al. 2005). Diabetics with good glucose control have 
higher EPC numbers and more functional EPCs when compared to diabetics with poorly 
controlled glucose (Churdchomjan, Kheolamai et al. 2010) and treating newly-diagnosed 
diabetics with secretagogues increases EPC numbers and is associated with a concordant 
improvement in endothelial function (Kusuyama, Omura et al. 2006; Liao, Chen et al. 2010). 
Likewise, insulin-sensitizing agents such as pioglitazone or rosiglitazone boost EPC 
numbers and the increase in EPCs is correlated with the reduction in C-reactive protein and 
increase in adiponectin (Kusuyama, Omura et al. 2006; Makino, Okada et al. 2008). The 
inverse relationship between EPC numbers and HbA1c and insulin resistance indices 
implies that EPC numbers decline in pre-diabetic states such as the metabolic syndrome and 
insulin resistance (Tepper, Galiano et al. 2002; Penno, Pucci et al. 2011). Indeed, EPC 
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numbers decrease as more metabolic syndrome criteria are met (Fadini, de Kreutzenberg et 
al. 2006; Jialal, Devaraj et al. 2010) and are also decreased in other pre-diabetic states such as 
gestational diabetes (Penno, Pucci et al. 2011) or the polycystic ovarian syndrome (Dessapt-
Baradez, Reza et al. 2011). Given that EPC numbers repair the vasculature and maintain 
endothelial dysfunction, this decreased capacity for repair of the vasculature may provide a 
mechanism for the increased risk of cardiovascular events observed in patients with the 
metabolic syndrome (Mottillo, Filion et al. 2010).    
5. Gender and age 
Age and male gender are irreversible cardiovascular risk factors. Healthy middle-aged women 
have higher EPC numbers than men (Hoetzer, MacEneaney et al. 2007). Young men have 
similar EPC numbers as post-menopausal women and this may explain why men are prone to 
cardiovascular disease at a younger age. Women, on average tend to develop cardiovascular 
disease after menopause with an incidence that equals that of age-matched men 10 years after 
the menopause. This time in a woman’s life, 10 years after the menopause, is associated with a 
decrease in EPC numbers and EPC function (Bulut, Albrecht et al. 2007; Rousseau, Ayoubi et 
al. 2010). This decline in EPC numbers may be due to the lack of estrogen since hyper-
estrogenic states (e.g. during ovarian stimulation) have been shown to be associated with an 
increase in EPC numbers and there is a normal variation with the ovarian cycle (Rousseau, 
Ayoubi et al. 2010). Hormone replacement therapy can boost EPC numbers in post-
menopausal females by 25% (Bulut, Albrecht et al. 2007) and enhance endothelial function 
(Sanada, Higashi et al. 2003; Kalantaridou, Naka et al. 2006).  
Ageing is associated with endothelial dysfunction and dysfunctional EPCs that are more 
prone to apoptosis and have reduced proliferative capacity (Heiss, Keymel et al. 2005; 
Kushner, Maceneaney et al. 2011). Further, the elderly are less able to mobilize EPCs in 
response to ischemic stimuli (Scheubel, Zorn et al. 2003). With ageing, the endothelial 
progenitor cells have shortened telomeres, which are the repetitive DNA at the ends of 
chromosomes that protect DNA integrity (Kushner, Van Guilder et al. 2009). Telomere 
shortening has been described in patients with CAD compared to healthy controls (Ogami, 
Ikura et al. 2004). Hence, this may provide a mechanism whereby EPCs from elderly 
individuals are more likely to undergo proliferative senescence and an increased susceptibility 
to apoptosis which can contribute to decreased EPC numbers. This generally occurs around 
the age of 55 which is temporally associated with the increased period of cardiovascular risk 
within a human’s lifetime (Kushner, Van Guilder et al. 2009). Hence, the ability to generate 
functional EPCs, to rejuvenate the endothelium lining the arteries and maintain endothelial 
function may be key in the pathogenesis of cardiovascular disease with aging. 
6. Hypertension 
Hypertension is associated with a doubling in the risk for cardiovascular disease with every 
20/10 mmHg increment (Chobanian, Bakris et al. 2003). Hypertension is associated with 
endothelial dysfunction and decreased EPC numbers and reduced EPC function (Vasa, 
Fichtlscherer et al. 2001; Umemura, Soga et al. 2008; Schulz, Gori et al. 2011). The treatment 
of hypertension, specifically with drugs inhibiting the renin-angiotensin system, is 
associated with increased EPCs whereas the use of other classes of drugs such as calcium 
antagonists, diuretics, and beta-blockers has not been associated with such effects 
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(Umemura, Soga et al. 2008). Similarly, treatment of diabetics with angiogentinsin receptor 
blockers boosts EPC numbers (Bahlmann, de Groot et al. 2005). Treating patients with an 
angiotensin-converting enzyme (ACE) inhibitor such as ramipril has similar effects 
(Bahlmann, de Groot et al. 2005). Angiotensin II reduces the proliferative capacity of 
cultured EPCs and induces cell death (Imanishi, Hano et al. 2005). Such observations may 
explain why drugs such as ACE inhibitors may have beneficial effects that are greater than 
the observed reduction in blood pressure (Yusuf, Sleight et al. 2000).   
7. Dyslipidemia 
Hypercholesterolemia is a pivotal cardiovascular risk factor and much there is much focus 
on treating this risk factor (ATP III 2002). Low density lipoprotein cholesterol (LDL-C) is the 
primary treatment target in both primary and secondary prevention of cardiovascular 
disease and there is a log-linear relationship between LDL-C level and CAD risk (ATP III 
2002). LDL-C is inversely correlated with EPC number and function in human patients 
(Chen, Zhang et al. 2004). Statin therapy has been shown to increase EPC numbers and 
function (Fadini, Albiero et al. 2010; Jaumdally, Goon et al. 2010) and to enhance EPC 
numbers in response to ischemic stimuli (Spadaccio, Pollari et al. 2010; Hibbert, Ma et al. 
2011). The improvement of endothelial function associated with statin use is directly 
correlated with the increase in EPC numbers and measures of EPC function (Higashi, 
Matsuoka et al. 2010). Similarly, lipid apheresis for resistant hypercholesterolemia improves 
EPC function and mobilization (Patschan, Patschan et al. 2009; Ramunni, Brescia et al. 2010). 
Low high density lipoprotein cholesterol (HDL-C) has been identified as secondary 
therapeutic target and reconstituted HDL-C infusion improves endothelial function and 
raises EPC numbers (Nieuwdorp, Vergeer et al. 2008).    
8. Inflammatory conditions 
Inflammatory conditions such as rheumatoid arthritis (RA) have, relative to traditional risk 
factors, been only recently associated with an increased cardiovascular risk. Like other 
cardiovascular risk factors, RA is associated with endothelial dysfunction (Herbrig, Haensel 
et al. 2006). Patients with RA have a life expectancy that is reduced by 5-10 years and the 
excess mortality is from cardiovascular disease which is increased roughly 4-fold (Wrigley, 
Lip et al. 2010). RA is particularly associated with a virulent form of coronary atherosclerosis 
characterized by high coronary artery calcium scores. However, the patients with RA that 
are at particular cardiovascular risk are those with active disease and high disease activity 
scores (Grisar, Aletaha et al. 2005). EPC numbers and EPC proliferative capacity show an 
inverse correlation with disease activity scores (Grisar, Aletaha et al. 2005; Herbrig, Haensel 
et al. 2006; Egan, Caporali et al. 2008). The increased risk of cardiovascular events is not 
limited to RA and has been described in other inflammatory states such as systemic lupus 
erythematosus (SLE) (Urowitz, Bookman et al. 1976; Roman, Shanker et al. 2003), human 
immunodeficiency virus (HIV) infection (van Leuven, Sankatsing et al. 2007), inflammatory 
bowel disease (Danese and Fiocchi 2003) or periodontitis (Mattila, Nieminen et al. 1989). 
Pre-menopausal women with SLE have a risk of myocardial infarction that is increased a 
staggering 50-fold compared to healthy controls (Manzi, Meilahn et al. 1997). SLE is 
associated with impaired EPC function and hence a decreased capacity to repair the 
endothelium (Deng, Li et al. 2010; Ablin, Boguslavski et al. 2011). Inflammatory conditions 
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are almost universally associated with increased inflammatory markers such as C-reactive 
protein (CRP) and cytokines such as tumor necrosis factor alpha (TNF-α) which is primarily 
made by macrophages and inhibits proliferation of repair cells in the body. CRP and TNF- α 
are directly toxic to EPCs; reducing survival and impairing function (Verma, Kuliszewski et 
al. 2004; Chen, Zhong et al. 2011). The number of EPCs in patients with inflammatory 
diseases such as Kawasaki’s disease is inversely correlated with plasma CRP and TNF- α 
(Xu, Men et al. 2010). Treating inflammatory disease such as RA with steroids or anti-TNF-α 
therapies boosts EPC numbers and may thus have salutary effects on cardiovascular health 
(Ablin, Boguslavski et al. 2006; Grisar, Aletaha et al. 2007).  
9. Physical activity 
A recent meta-analysis has shown that individuals exercising ~150 minutes at moderate 
intensity have a 14% lower risk of CAD compared to sedentary individuals (Sattelmair, 
Pertman et al. 2011). There was a dose-response relationship with higher grades of physical 
activity associated with proportional reductions in incident CAD. In patients with CAD, 
exercise-based rehabilitation is associated with a 20% reduction in mortality and a 26% 
reduction in cardiac mortality (Taylor, Brown et al. 2004). Exercise enhances endothelial 
function and increases NO bioavailability (Hambrecht, Adams et al. 2003; Green, Maiorana 
et al. 2004; Higashi and Yoshizumi 2004). Since EPC number is a fundamental determinant 
of endothelial function, it would be expected that exercise mobilizes EPCs. Indeed, a three 
month exercise prescription in humans increases EPC numbers and this independent of the 
effects of exercise on body mass, adiposity, blood pressure or lipids (Hoetzer, Van Guilder 
et al. 2007). Importantly, the improvement in endothelial function correlated with the 
increase in the number of circulating EPCs (r=0.81, p<0.001) and the increase in NO 
synthesis (Steiner, Niessner et al. 2005). This suggests that exercise-induced EPC 
mobilization enhances vascular repair. Exercise may also halt atherosclerotic disease 
progression as ascertained in both the coronary and carotid beds (Belardinelli, Paolini et al. 
2001; Hambrecht, Walther et al. 2004; Rauramaa, Halonen et al. 2004). While multiple 
studies have shown exercise to mobilize EPCs, the total amount of physical activity has been 
associated directly with EPC numbers which is consistent with a dose-response (Adams, 
Lenk et al. 2004; Sandri, Adams et al. 2005; Luk, Dai et al. 2009). Of great interest is the 
intensity of exercise required to mobilize EPCs. Most protocols have described symptom-
limited exercise testing that is of a vigorous nature (Adams, Lenk et al. 2004; Rehman, Li et 
al. 2004; Sandri, Adams et al. 2005). While 10 minutes of moderate (~70% of VO2 max) 
exercise did not increased circulating EPC numbers, 30 minutes of moderate or intense 
(~80% VO2 max) exercise increased EPC numbers (Laufs, Urhausen et al. 2005). This level of 
intensity is approximately consistent with guideline recommendations for the secondary 
prevention of CAD (Smith, Allen et al. 2006).  
10. Conclusion: A paradigm for cardiovascular risk assessment 
From the above discussion, it is clear that cardiovascular risk factors individually and 
collectively decrease EPC number and function. This includes traditional risk factors such as 
age, gender, lipids, hypertension and smoking as well as emerging risk factors such as 
inflammatory diseases and risk factors that are difficult to quantify such as a family history 
of vascular disease. Moreover, EPC numbers respond to risk factor modification and thus 
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may provide a dynamic assessment of cardiovascular risk. EPC numbers correlate directly 
with endothelial function and inversely with Framingham risk score in asymptomatic 
individuals (Hill, Zalos et al. 2003; Ghani, Shuaib et al. 2005; Chironi, Walch et al. 2007). EPC 
numbers correlate inversely with the number of vascular beds with subclinical disease in 
asymptomatic patients (Chironi, Walch et al. 2007) and with cardiovascular disease 
surrogates such as carotid intima-media thickness after correction for the Framingham risk 
score and CRP (Fadini, Coracina et al. 2006). We believe that the measurement of EPCs 
represents a unique opportunity for cardiovascular risk assessment in the primary 
prevention setting. While patients in the low risk category by traditional risk factors are 
unlikely to have their risk category altered by EPC measurement, EPC measurement could 
be of great utility in the asymptomatic patient at intermediate risk of cardiovascular disease. 
Such a patient could be re-categorized into a low risk category if their EPC count is high or 
could be deemed suitable for the commencement of medications for risk factor control if the 
EPC count is low and categorizes the patient at higher risk. Patients who are at high risk by 
traditional risk-assessment tools or who have established cardiovascular disease would 
need treatment and would be unlikely to have high EPC counts. This proposed paradigm is 
illustrated in Figure 1.  
 
Fig. 1. A Proposed Paradigm for the Prevention of Cardiovascular Disease Utilizing EPCs  
The measurement of EPC utilizes flow cytometry which is available in many metropolitan 
hospitals. The cost of a single EPC count is relatively low costing ~35AUD (30€ or $40USD) 
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if EPCs are defined as CD34+KDR+ cells. However, there are several barriers to the 
implementation of EPC number as a cardiovascular risk prognosticator. Firstly, there is lack 
of universal agreement on the surface markers that define EPCs. While most studies define 
EPCs as CD34+KDR+ cells, others also utilize the AC133 surface marker. We propose that 
the CD34+KDR+ definition should be utilized since EPC number measured in this way have 
predicted cardiovascular events (Schmidt-Lucke, Rossig et al. 2005; Werner, Kosiol et al. 
2005; Kunz, Liang et al. 2006; Wang, Gao et al. 2007). The second major barrier to the 
implementation of EPC number in routine cardiovascular risk assessment is the lack of 
established “normal” and “at risk” levels. These need to be established from primary 
prevention cohorts and can be measured retrospectively in one cohort and then validated in 
another. Thirdly, a set of standards for the measurement of EPC numbers will be required. 
This would include studies on the normal biological variability of EPC numbers and 
accepted standards for acceptable intra-measurement and inter-measurement coefficients of 
variation. However, this marker of cardiovascular risk has many advantages which include 
integrating cardiovascular risk in a single measurement and followed serially to assess the 
impact of risk factor modification on cardiovascular risk.  
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